During the corresponding time, Gyre Therapeutics Inc recorded a revenue increase by 8.72 % year on year, sequentially revenue grew by 29.25 %. While revenue at the Gyre Therapeutics Inc 's corporate clients
Gyre Therapeutics Inc's Comment on Sales, Marketing and Customers
The company operates in the pharmaceutical market in the People's Republic of China, with in-house sales and marketing coverage across 30 provinces, autonomous regions, and municipalities. Its sales and marketing team comprises 405 employees experienced in pharmaceutical sales, focusing on establishing and maintaining relationships with regional outlets. The company's inventory includes raw materials, work-in-progress, semi-finished goods (APIs), and finished products to support continuous production. Logistics services are outsourced to third parties under agreements that ensure safe and timely delivery. Manufacturing takes place at in-house facilities in Beijing and Cangzhou, Hebei province, compliant with cGMP regulations and overseen by a quality management team adhering to NMPA regulations.
In a landmark achievement recently reported by Gyre Therapeutics Inc. (NASDAQ: GYRE), the company s lead candidate, Hydronidone, has successfully met its primary endpoint in a pivotal Phase 3 trial aimed at treating chronic hepatitis B (CHB)-associated liver fibrosis in China. This remarkable finding signals a turning point in the field of liver disease treatment, opening new avenues for patients suffering from this debilitating condition.Hydronidone did not just meet expectations; it surpassed them by demonstrating statistically significant regression of liver fibrosis, a crucial parameter in assessing therapeutic efficacy. This breakthrough is of paramount importance, as liver fibrosis can progress to cirr...
Gyre Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company operates in the pharmaceutical market in the People's Republic of China, with in-house sales and marketing coverage across 30 provinces, autonomous regions, and municipalities. Its sales and marketing team comprises 405 employees experienced in pharmaceutical sales, focusing on establishing and maintaining relationships with regional outlets. The company's inventory includes raw materials, work-in-progress, semi-finished goods (APIs), and finished products to support continuous production. Logistics services are outsourced to third parties under agreements that ensure safe and timely delivery. Manufacturing takes place at in-house facilities in Beijing and Cangzhou, Hebei province, compliant with cGMP regulations and overseen by a quality management team adhering to NMPA regulations.
Sources:
Gyre Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Gyre Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Gyre Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
168.1 %